According to Bloomberg News Celgene Corp. said it will stop a study (Mainsail) of its blood-cancer pill Revlimid as a treatment for prostate cancer because the drug failed to help patients more than chemotherapy and steroids alone.

This conclusion was drawn after the data-monitoring panel found the drug did not meet its primary goal of prolonging survival in men with castrate-resistant prostate cancer.

Joel T Nowak, M.A., M.S.W.